3 Soaring Stocks That May Have More Upside Ahead

The article highlights three stocks with big recent runs—Abivax (+1,500% over 12 months), Krystal Biotech (+167%), and Marvell Technology (+248%)—arguing they still have upside. For Krystal Biotech, Q1 revenue rose 32% YoY to $116.4M and net profit increased 56.5% YoY to $55.9M, driven by Vyjuvek performance. For Marvell, fiscal Q1’27 net revenue hit a record $2.4B (+28% YoY) and adjusted EPS rose 29% YoY to $0.80, supported by rising AI infrastructure ASIC demand.

Analysis

This is less a “buy the news” setup than a reminder that the market is paying up for two very different kinds of optionality: self-funding commercial scarcity in KRYS and binary clinical upside in ABVX. The spread matters—KRYS can compound on its own cash flow, while ABVX still has to survive a long regulatory gap, so any valuation rerate is hostage to safety, approval, and eventual reimbursement friction rather than just efficacy.

The cleaner second-order winner is MRVL as a relative beneficiary of hyperscaler diversification away from NVDA. The real constraint is customer concentration: if a few cloud buyers delay or internalize ASIC design, revenue can look strong until one program slips, so the next 2-3 earnings cycles matter more than the 6-18 month AI narrative. AVGO is the obvious competitor to watch, but the broader point is that custom silicon is a share-shift story inside AI capex, not a guarantee of unbounded industry growth.

Contrarian take: the market may be overpricing “early innings” across the board. ABVX’s window to approval is long enough for sentiment and funding conditions to change; KRYS already reflects a lot of execution quality; and MRVL may be the better stock, but not necessarily the better trade if AI spend broadens instead of re-prices toward custom chips. For now, the highest-probability expression is relative value rather than outright beta chasing.

Key Decisions for Investors

• Long KRYS vs. XBI/IBB on a 1-3 month horizon; add on 8-12% pullbacks. Thesis is durable cash-flow compounding and orphan-market scarcity. Falsify if prescription growth slows materially or gross margin starts to compress.
• Use MRVL as a tactical long against NVDA or AVGO into the next 1-2 earnings cycles; keep size modest because hyperscaler concentration can make quarterly guidance noisy. Falsify on decelerating data-center growth or weaker custom-silicon commentary.
• Do not chase ABVX after the move; keep it on a watchlist until the Crohn’s data or the 2026 filing path reduces binary risk. If the stock retraces ~25% while safety remains clean, reconsider a small speculative position.
• For broader AI exposure, prefer a basket approach: long MRVL, paired with a smaller hedge in SOXX or NVDA if you want to isolate ASIC share gains from sector beta. The trade works only if custom-chip mix continues to expand faster than the overall AI capex cycle.